800.227.0627

Writers, Readers, and Erasers of RNA Modifications

Because of many recent improvements made in the last decades in automated synthesis of biomolecules such as oligonucleotides (DNA/RNA), polypeptides, carbohydrates, and modified derivatives of these, and in high-resolution and sensitive analytical instruments, our understanding of cells, cell structures and their dynamics at the molecular level has dramatically increased. A collection of human genomes is now available, scientists studied the 3D organization of the genome, and a data set of genomes is available at the ATCC genome portal: Human Genome Collection.Initial sequencing and analysis of the human genome | NatureGenomes | ATCC Genome Portal.

Molecular medicine aims to link “omic” approaches to cancer research. Understanding and characterizing metabolism in cancer and healthy cells is the key to developing new specific and efficient therapeutics targeting cancer cells. The knowledge of possible marks and their functions on biomolecules involved in the metabolism of human cells is expected to create a comprehensive picture of human and tumor biology at the systems and molecular level.

Multi-omics approaches enable the characterization and quantification of regulatory marks in the genome, the epigenome, the transcriptome, the epitranscriptome, the proteome, and the epiproteome. This knowledge is expected to increase our understanding of eukaryotic metabolism and physiology, helping to create improved personalized therapeutics.

Research conducted during the last decades revealed that cancer is a disease driven by genetic mutations, epigenetic modifications, a misregulated transcriptome, now known as the epitranscriptome, and a misregulated proteome, known as the epiproteome. The so-called epitranscriptome is now understood as the chemical modifications of RNA that regulates and alters the activity of RNA molecules. An example is the hypermethylation of DNA associated with silencing tumor suppressor genes and aberrant histone modifications. A signaling pathway project is underway to integrate an “omics” knowledgebase for mammalian cellular signaling pathways. This database contains curated data sets validated using alignment with the canonical literature knowledge and gene target-level integration of transcriptomic and cistromic data points. [
Signaling pathways Project]

Research in recent decades has made it clear that the addition or removal of RNA modifications in various RNA species regulates a broad spectrum of RNA regulatory processes. These RNA-regulating processes regulate specific sets of genes. Therefore, the context of the RNA molecule and the RNA effector enzymes involved determine the molecular destiny of any given RNA transcript. Interestingly, subcellar localization of both RNAs and RNA-modifying proteins, the number of transcripts of specific cellular RNAs, the various RNA types, the folding of RNAs, RNA-protein interactions, and responses to stimuli such as DNA or RNA damage determine the metabolisms of RNA modifications. Defects in any of these processes may lead to cancer progression. Table 1 illustrates the interplay of “omics” systems.


Table 1: "Omics" Systems 

Genome

DNA

Epigenome

DNA modified: 5hmC, 5mC, 5fC, 3mC, 4mC, 6mA.

Transcriptome

RNA:

rRNA, tRNA, snRNA, mRNA, lncRNA, miRNA, etc.

Epitranscriptome

RNA modified:

Ψ, m5C, m1A, m6A, m5A, etc.

Proteome

Proteins

Epiproteome

Proteins modified:

PTMs.

SNP

CNV

LOH

Rearrangement

DNA modifications:

methylation

Alternative splicing RNA editing

RNA modifications:

methylation, pseudouridylation, acetylation, A-t-I, ribose methylation, others.

Protein isoforms

Peptides and micropeptides.

Protein post-translational modifications (PTMs):

methylation, phosphorylatin, glycosylation, ubiquitination, nitrosylation, SUMOylation.

NGS, WES

WGS, FISH, CGH

ChiP-seq

DNA microarray

Targeted DNA seq

DNA methylation array

Pyrosequencing

Bisulfite sequencing (BS)

RNA seq, SLAM-seq,

RNA microarray

Targeted RNA seq,

RNA Exome Capture Seq

Ribosome profiling

qRT-PCR

Methylated RNA IP-seq, miCLIP, RNA BS-seq, m1A/m6A-seq,

DART-seq

Quantification of RNA mods by LC-MS

Mass Spectrometry

Protein Array

Immuno-precipitation

Immuno-fluorescence

Western Blot Analysis

Mapping PTMs by mass spectrometry (LC-MS/MS)

SILAC, HPLC

Phospho-Kinase array

Western Blot Analysis


Legend
: CGH = comparative genomic hybridization, ChiP-seq = chromatin immunoprecipitation DNA sequencing, CNV = copy number variation, DART-seq = Diversity Arrays Technology, FISH = fluorescence in situ hybridization, LOH = loss of heterozygosity, NGS = next generation sequencing, SILAC = Stable isotope labeling by amino acids in cell culture, SNP = single-nucleotide polymorphism, WES = whole exome sequencing.

 Table 2: RNA Modifications and Enzymes

  Important RNA modifications

  Enzymes that modify RNA

 m1A: 1-methyladenosine,

 ms2i6A: 2-methylthio-N6-isopentenyl-adenosine,

 i6A: N6-isopentenyladenosine,

 m6A: N6-methyladenosine,

 m3C: 3-methylcytosine,

 m5C: 5-methylcytosine,

 ac4C: N4-acetylcytosine,

 m7Gpp(pN): 7-methylguanosine cap,

 m7G: 7-methylguanosine internal,

 m2,2G: N2,N2,-dimethylguanosine,

 m2G: N2-methylguanosine,

 Q: queuosine, yW et al.: Wybutosine and derivatives,

 m5U: 5-methyluridine,

 ncm5U: 5-carbamoyl-methyluridine,

 mcm5U: 5-methoxycarbonyl-methyluridine,

 mcm5s2U: 5-methoxycarbonylmethyl-2-thiouridine,

 D: dihydrouridine,

 Ψ: pseudouridine,

 Nm: 2-O-Methylnucleotide,

 m(pN): 5phosphate monomethylation,

 A-to-I: Deamination of Adenosine,

 C-to-U: Deamination of Cytosine.

 

 ADAR1-3: Adenosine Deaminase RNA Specific 13,

 ALKBH1/3/5/8: AlkB Homolog 1/3/5/8,

 APOBEC1/3G: Apolipoprotein B mRNA Editing
 Enzyme Catalytic Subunits 1/3G,

 BCDIN3D: BCDIN3 Domain Containing
 Methyltransferase,

 BUD23: RRNA Methyltransferase And Ribosome
 Maturation Factor,

 CDK5RAP1: CDK5 Regulatory Subunit Associated Protein 1,

 CMTR1/2: Cap Methyltransferase 1/2,

 CTU1/2: Cytosolic Thiouridylase Subunit 1/2,

 DKC1: Dyskerin Pseudouridine Synthase 1,

 DNMT2: tRNA Aspartic Acid Methyltransferase 1,

 DUS2: Dihydrouridine Synthases 2,

 ELP3: Elongator Acetyltransferase Complex Subunit 3,

 FTO: FTO Alpha-Ketoglutarate Dependent Dioxygenase,

 HENMT1: HEN Methyltransferase 1,

 METTL1/2/3/6/8/14/16: Methyltransferase Like-1/2/3/6/8/16,

 NAT10: N-Acetyltransferase 10,

 NSUN1-5: NOP2/Sun RNA Methyltransferase 15,

 NUDT16: Nudix Hydrolase 16,

 RNMT: RNA Guanine-7 Methyltransferase,

 TGT: Queuine TRNA-Ribosyltransferase Catalytic Subunit 1,

 TRIT1: tRNA Isopentenyltransferase 1,

 TRMT1/2A/2B1/5/6/10C/11/61A/61B/112:
  tRNA Methyltransferase Subunits,

 TYW2: tRNA-YW Synthesizing Protein 2 Homolog.

 


RNA modifications known as epitranscriptomic marks





 



 

 



 



 

 



Table 3: Epitrancriptome of small non-coding RNAs

 

SncRNAs Species

Described Chemical Modifiction

Writers

Readers

miRNA

m6A

METTL3/ METTL14

HNRNPA2B1/ HNRNPC

m7G

METTL1

/

2′-O-Me

HEN1

/

5′Pme2

BCDIN3D

/

Uridylation

TUT7/4/2

/

A to I

ADARs

/

o8G

/

/

8-OHG

/

/

piRNA

2′-O-Me

HEN1

 

snRNA

Ψ

Box H/ACA RNP/ Pus1 and Pus7

/

2′-O-Me

Box C/D RNP

/

m6A

METTL16

/

m6Am

METTL4

/

TMG

TGS1

/

m5C

/

YPS

snoRNA

Ψ

Box H/ACA RNP

/

m6A

/

/

tsRNA

m5C

DNMT2/ NSUN2

/

m2G

DNMT2

/

Q

QTRT1/QTRT2

/

2′-O-Me

TRM7/FTSJ1

/

m1A

TRMT6/61A

/

m3C

METTL2/ METTL6

/

m1G

TRMT10A

/

hm5C

TET2

/

Ψ

PUS7

/

mcm5S2

/

/

 (Source: Li et al. 2021; Wang et al. 2022)



Reference

Esteve-Puig R, Bueno-Costa A, Esteller M. Writers, readers and erasers of RNA modifications in cancer. Cancer Lett. 2020 Apr 1;474:127-137. [PubMed]

Li X, Peng J, Yi C. The epitranscriptome of small non-coding RNAs. Noncoding RNA Res. 2021;6(4):167-173. [PMC]

Signaling pathways Project

Wang S, Li H, Lian Z, Deng S. The Role of RNA Modification in HIV-1 Infection. Int J Mol Sci. 2022;23(14):7571. [PMC]


---...---

Bio-Synthesis provides a full spectrum of oligonucleotide and peptide synthesis including bio-conjugation services as well as high quality custom oligonucleotide modification services, back-bone modifications, conjugation to fatty acids and lipids, cholesterol, tocopherol, peptides as well as biotinylation by direct solid-phase chemical synthesis or enzyme-assisted approaches to obtain artificially modified oligonucleotides, such as BNA antisense oligonucleotides, mRNAs or siRNAs, containing a natural or modified backbone, as well as base, sugar and internucleotide linkages.

Bio-Synthesis also provides biotinylated mRNA and long circular oligonucleotides.
---...---